Previous deals in this sector were valued at US$500M in a mix of upfronts and milestone payments. 26c would imply only a 30% premium on heavily oversubscribed IPO. I think somewhere around current levels is fair. It should be several hundred $M in valuation once clinical trials commence.
IPO - Chimeric Therapeutics Limited - 18 January 2021 #, page-280
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.89M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.8¢ | 1.7¢ | $11.13K | 639.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1637611 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 13500 | 1 |
View Market Depth
| Last trade - 15.59pm 02/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |